Canine Fibroblast Growth Factor 21 Ameliorates Hyperglycemia Associated with Inhibiting Hepatic Gluconeogenesis and Improving Pancreatic Beta-Cell Survival in Diabetic Mice and Dogs

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 May 21

PMID 27203422

Citations 3

Authors

Pengfei Xu

Yingjie Zhang

Xinghao Jiang

Junyan Li

Liying Song

Mir Hasson Khoso

Yunye Liu

Qiang Wu

Guiping Ren

Deshan Li

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus is a common endocrinopathy in dog. Fibroblast growth factor 21 (FGF-21) is a secreted protein, which is involved in glucose homeostasis. We speculate that the recombinant canine FGF-21 (cFGF-21) has the potential to become a powerful therapeutics to treat canine diabetes. The cFGF-21 gene was cloned and expressed in E. coli Rosetta (DE3). After purification, a cFGF-21 protein with the purity exceeding 95% was obtained. Mouse 3T3-L1 adipocytes and type 1 diabetic mice/dogs induced by STZ were used to examine the biological activity of cFGF-21 in vitro and in vivo, respectively. Results showed that cFGF-21 stimulated glucose uptake in adipocytes significantly in a dose-dependent manner, and reduced plasma glucose significantly in diabetic mice/dogs. After treatment with cFGF-21, the serum insulin level, glycosylated hemoglobin (HbA1c) level and the expressions of the hepatic gluconeogenesis genes (glucose-6-phosphatase, G6Pase and phosphoenolpyruvate carboxykinase, PCK) of the diabetic mice/dogs were attenuated significantly. In the mouse experiment, we also found that the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and the expression of suppressor of cytokine signaling 3 (SOCS3) were up-regulated significantly in the livers after treatment. Histopathological and immunohistochemical results showed that treatment with cFGF-21 promoted recovery of pancreatic islets from STZ-induced apoptosis. Besides, we also found that treatment with cFGF-21 protected liver against STZ or hyperglycemia induced damage and the mechanism of this action associated with inhibiting oxidative stress. In conclusion, cFGF-21 represents a promising candidate for canine diabetes therapeutics. The mechanism of cFGF-21 ameliorates hyperglycemia associated with inhibiting hepatic gluconeogenesis by regulation of STAT3 signal pathway and improving pancreatic beta-cell survival.

Citing Articles

Synergistic effect of canine FGF-21 combined with insulin in the treatment of canine diabetes.

Sun W, Wang Y, Liu Z, Wu Q, Guo X, Li Z Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39836254 DOI: 10.1007/s00210-025-03803-x.

Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats.

Brinker E, Towns T, Watanabe R, Ma X, Bashir A, Cole R Front Vet Sci. 2023; 10:1072680.

PMID: 36756310 PMC: 9900002. DOI: 10.3389/fvets.2023.1072680.

FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH).

Urraza-Robledo A, Giralt M, Gonzalez-Galarza F, Villarroya F, Miranda Perez A, Ruiz Flores P PLoS One. 2021; 16(5):e0252144.

PMID: 34019585 PMC: 8139451. DOI: 10.1371/journal.pone.0252144.

Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease.

Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P J Clin Exp Hepatol. 2019; 9(5):607-618.

PMID: 31695251 PMC: 6823706. DOI: 10.1016/j.jceh.2018.10.004.

References

Catchpole B, Adams J, Holder A, Short A, Ollier W, Kennedy L . Genetics of canine diabetes mellitus: are the diabetes susceptibility genes identified in humans involved in breed susceptibility to diabetes mellitus in dogs?. Vet J. 2012; 195(2):139-47. DOI: 10.1016/j.tvjl.2012.11.013. View

Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K . Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med. 2004; 10(2):168-74. DOI: 10.1038/nm980. View

Howard J, Flier J . Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab. 2006; 17(9):365-71. DOI: 10.1016/j.tem.2006.09.007. View

Genet S, Kale R, Baquer N . Alterations in antioxidant enzymes and oxidative damage in experimental diabetic rat tissues: effect of vanadate and fenugreek (Trigonellafoenum graecum). Mol Cell Biochem. 2002; 236(1-2):7-12. DOI: 10.1023/a:1016103131408. View

Niessen S, Powney S, Guitian J, Niessen A, Pion P, Shaw J . Evaluation of a quality-of-life tool for cats with diabetes mellitus. J Vet Intern Med. 2010; 24(5):1098-105. DOI: 10.1111/j.1939-1676.2010.0579.x. View

Nishimura T, Nakatake Y, Konishi M, Itoh N . Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000; 1492(1):203-6. DOI: 10.1016/s0167-4781(00)00067-1. View

Marcovecchio M, Chiarelli F . Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr Nephrol. 2010; 26(3):365-75. DOI: 10.1007/s00467-010-1624-9. View

Catchpole B, Kennedy L, Davison L, Ollier W . Canine diabetes mellitus: from phenotype to genotype. J Small Anim Pract. 2007; 49(1):4-10. DOI: 10.1111/j.1748-5827.2007.00398.x. View

Sato T, Toyoshima A, Hiraki T, Ohta Y, Katayama K, Arai T . Effects of metformin on plasma concentrations of glucose and mannose, G6Pase and PEPCK activity, and mRNA expression in the liver and kidney of chickens. Br Poult Sci. 2011; 52(2):273-7. DOI: 10.1080/00071668.2011.560595. View

10.

Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, Wan X . High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol. 2010; 10:14. PMC: 2831817. DOI: 10.1186/1472-6750-10-14. View

11.

Xu J, Lloyd D, Hale C, Stanislaus S, Chen M, Sivits G . Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2008; 58(1):250-9. PMC: 2606881. DOI: 10.2337/db08-0392. View

12.

Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M . Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006; 3(4):267-75. DOI: 10.1016/j.cmet.2006.02.009. View

13.

Rand J, Fleeman L, Farrow H, Appleton D, Lederer R . Canine and feline diabetes mellitus: nature or nurture?. J Nutr. 2004; 134(8 Suppl):2072S-2080S. DOI: 10.1093/jn/134.8.2072s. View

14.

Coskun T, Bina H, Schneider M, Dunbar J, Hu C, Chen Y . Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149(12):6018-27. DOI: 10.1210/en.2008-0816. View

15.

Arai T, Nakamura M, Magori E, Fukuda H, Mizutani H, Kawakami E . Changes in activities of enzymes related to energy metabolism in peripheral leukocytes of diabetic dogs with glycemic control by intensive insulin treatment. Res Vet Sci. 2002; 73(2):183-6. DOI: 10.1016/s0034-5288(02)00104-2. View

16.

Niessen S, Fernandez-Fuente M, Mahmoud A, Campbell S, Aldibbiat A, Huggins C . Novel diabetes mellitus treatment: mature canine insulin production by canine striated muscle through gene therapy. Domest Anim Endocrinol. 2012; 43(1):16-25. DOI: 10.1016/j.domaniend.2012.01.006. View

17.

Wente W, Efanov A, Brenner M, Kharitonenkov A, Koster A, Sandusky G . Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006; 55(9):2470-8. DOI: 10.2337/db05-1435. View

18.

Consoli A, Nurjhan N, Capani F, Gerich J . Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes. 1989; 38(5):550-7. DOI: 10.2337/diab.38.5.550. View

19.

Ye D, Wang Y, Li H, Jia W, Man K, Lo C . Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice. Hepatology. 2014; 60(3):977-89. DOI: 10.1002/hep.27060. View

20.

Sindhu R, Koo J, Roberts C, Vaziri N . Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clin Exp Hypertens. 2004; 26(1):43-53. DOI: 10.1081/ceh-120027330. View